The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio, Inc. reported new responder analyses from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at EAACI2026.
The results indicate that most participants receiving the treatment achieved clinically meaningful improvements across key endpoints, underscoring the potential of verekitug in this patient population. The data presentation highlights ongoing efforts to address unmet medical needs in CRSwNP. Upstream Bio, Inc. continues to evaluate verekitug in clinical trials as part of its research portfolio.
View post on X Loading...
Upstream Bio, Inc. has increased industry visibility in recent months. CEO Rand Sutherland was scheduled to speak at the Goldman Sachs Annual Global Healthcare Conference via live webcast. The company also planned a fireside chat at a healthcare event in Miami earlier this month.